LeMaitre Vascular, Inc.
LMAT
Positions held
Your positionsLMAT isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- LeMaitre Vascular operates in a growing healthcare sector, focusing on innovative medical instruments that address vascular diseases, which is critical as the aging population increases demand for such solutions.
- In Q2 2026, LeMaitre reported a revenue of $70.382 million, reflecting a 6% increase compared to the previous quarter.
- The company achieved a gross margin of 72.1% in Q2 2026, demonstrating strong profitability despite competitive pressures.
- The stock has a 'Strong Sell' signal, indicating potential challenges in maintaining investor confidence amidst market volatility.
- LeMaitre's operating margin decreased to 28.98% in Q2 2026 from 29.22% in Q4 2025, suggesting a decline in operational efficiency.
- The company's score indicates a negative trend with a score of -15.00, highlighting concerns over its performance relative to market benchmarks.
Fundamentals
| Market cap | $1.82B | Enterprise value | $1.64B | Trailing P/E | 27.94 | Forward P/E | 25.05 |
| PEG | 2.10 | Price / book | 4.33 | Beta | 0.47 | Dividend yield | 1.26% |
| Revenue growth | 9.6% | Earnings growth | 22.6% | Gross margin | 71.9% | Operating margin | 29.0% |
| Profit margin | 25.0% | ROE | 16.8% | ROA | 7.4% | Debt / equity | 0.45 |
| Current ratio | 16.31 | Free cash flow | $49.26M | Analyst recommendation | buy | Mean target | $107.00 |
| 52w high | $118.01 | 52w low | $78.22 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $70.4M | $66.6M | $64.5M | $61.0M | $64.2M | — |
| Op margin | 29.0% | 26.7% | 29.2% | 33.3% | 25.1% | — |
| Net income | $17.1M | $15.7M | $15.6M | $17.4M | $13.8M | — |
| Gross margin | 72.1% | 72.7% | 71.7% | 75.3% | 70.0% | — |
| Gross profit | $50.8M | $48.4M | $46.2M | $46.0M | $45.0M | — |
| Operating income | $20.4M | $17.8M | $18.8M | $20.3M | $16.1M | — |
- Revenue +6% vs prior quarter ($70M vs $67M).
- Gross margin 72.1% (was 72.7% prior quarter).
- Operating margin expanded to 29%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $250M | $220M | $193M | $162M | — |
| Op margin | 27.2% | 23.8% | 19.2% | 18.5% | — |
| Net income | $57.7M | $44.0M | $30.1M | $20.6M | — |
| Gross margin | 71.5% | 68.6% | 65.7% | 64.9% | — |
| Gross profit | $179M | $151M | $127M | $105M | — |
| Operating income | $67.9M | $52.3M | $37.2M | $29.9M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-06 · 1 of Wall Street’s Favorite Stocks to Own for Decades and 2 We Brush Off
2026-09-24 · Is LeMaitre Vascular (LMAT) A Bargain Following Its 90 Day Pullback?
2026-09-24 · LeMaitre Vascular (LMAT) Stock Looks Fully Priced On Its 57% Five Year Run
2026-09-22 · 3 Small-Cap Stocks We Steer Clear Of
2026-09-21 · 2 Profitable Stocks to Target This Week and 1 We Ignore
2026-09-04 · 3 Out-of-Favor Stocks with Questionable Fundamentals
2026-09-02 · PAHC or LMAT: Which Is the Better Value Stock Right Now?
2026-09-01 · Speculative Rally Weighed on LeMaitre Vascular (LMAT)
2026-08-27 · LeMaitre to Participate at Upcoming Investor Conferences in September
2026-08-13 · GEHC or LMAT: Which Is the Better Value Stock Right Now?
2026-08-13 · The Top 5 Analyst Questions From LeMaitre’s Q2 Earnings Call
Price (daily)
Full chart · RSI · MACD · patterns